Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Glioblastoma multiforme (GBM; WHO astrocytoma grade IV) is considered incurable owing
to its inherently profound resistance towards current standards of therapy. Considerable …

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM)
and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ …

Highlights•Temozolomide resistance can be induced by glioblastoma cells.•Resistance to
temozolomide is caused by multiple mechanisms.•Different resistance pathways exist in …

Abstract Treatment for glioblastoma multiforme includes the alkylating agent temozolomide
combined with ionizing radiation. Persistent O6-guanine methylation by temozolomide in O6 …

Many conventional chemotherapeutic drugs exert their cytotoxic function by inducing DNA
damage in the tumor cell. Therefore, a cell-inherent DNA repair pathway, which reverses the …

Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality
rate. Although the current standard therapy consists of surgery followed by radiation and …

Glioma is one of the most common and lethal brain tumors. Surgical resection followed by
radiotherapy plus chemotherapy is the current standard of care for patients with glioma. The …

Background The use of temozolomide (TMZ) has improved the prognosis for glioblastoma
multiforme patients. However, TMZ resistance may be one of the main reasons why …